Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.

HIV medicine - 1 Mar 2006

Hill A, Walmsley S, Clotet B, Molto J

Abstract excerpt

There is a need for new, clinically relevant interpretation algorithms for genotypic and phenotypic resistance for ritonavir-boosted saquinavir (SQV/r) at the current approved dosage [1000/100 mg twice a day (bid)]. Clinical cut-off levels, which correlate baseline measures of resistance with HIV RNA responses in large cohorts or clinical trials, are the ideal reference for developing such algorithms. Cut-off...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Algorithms
Share to Drug Resistance, Viral
Share to Drug Therapy, Combination

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Genotype

Share to HIV Protease Inhibitors

Share to Ritonavir

Share to Saquinavir

Source

Identifiers

PMID: 16420251
DOI: 10.1111/j.1468-1293.2006.00351.x

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Analysis of genotypic and phenotypic clinical cut-off levels for ritonavir-boosted saquinavir.PMID 16420251Read ↗

Predictive value of drug levels, HIV genotyping, and the genotypic inhibitory quotient (GIQ) on response to saquinavir/ritonavir in antiretroviral-experienced HIV-infected patients.Semantic proximity Read ↗

Baseline antiretroviral drug susceptibility influences treatment response in patients receiving saquinavir-enhancing therapy.Semantic proximity Read ↗

Clinically relevant interpretation of genotype and relationship to plasma drug concentrations for resistance to saquinavir-ritonavir in human immunodeficiency virus type 1 protease inhibitor-experienced patients.Semantic proximity Read ↗

Plasma drug levels, genotypic resistance, and virological response to a nelfinavir plus saquinavir-containing regimen.Semantic proximity Read ↗

Impact of HIV genotyping and drug levels on the response to salvage therapy with saquinavir/ritonavir.Semantic proximity Read ↗

Absence of resistance mutations in antiretroviral-naive patients treated with ritonavir-boosted saquinavir.Semantic proximity Read ↗

The rabbit study: ritonavir and saquinavir in combination in saquinavir-experienced and previously untreated patients.Semantic proximity Read ↗

Determination of clinically relevant cutoffs for HIV-1 phenotypic resistance estimates through a combined analysis of clinical trial and cohort data.Semantic proximity Read ↗

Efficacy, tolerance, and pharmacokinetics of the combination of stavudine, nevirapine, nelfinavir, and saquinavir as salvage regimen after ritonavir or indinavir failure.Semantic proximity Read ↗

Rational approaches to resistance: using saquinavir.Semantic proximity Read ↗

Pharmacokinetics and resistance mutations affect virologic response to ritonavir/saquinavir-containing regimens.Semantic proximity Read ↗

Clinical cross-resistance between the HIV-1 protease inhibitors saquinavir and indinavir and correlations with genotypic mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.